Skip to main navigation Skip to search Skip to main content

A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

Project: Research project

Project Details

StatusFinished
Effective start/end date8/12/16 → 6/30/17

Funding

  • Novartis Pharmaceuticals Corporation ( Award # ): $152,162.92